Document:

<PAGE>

                                                                    EXHIBIT 10.1

                           COMMON STOCK ACQUISITION
                                   AGREEMENT

          COMMON STOCK ACQUISITION AGREEMENT dated as of March 22, 1996 between
                                                               --
Genomica Corporation, a Delaware corporation (the "Company"), and [      ] (the
"Purchaser").

          WHEREAS the Company wishes to sell an aggregate of [      ] shares of
the Company's Common Stock, $.001 par value per share, (the "Shares") to the
Purchaser; and

          WHEREAS the Purchaser wishes to purchase the Shares on the terms and
subject to the conditions set forth in this Agreement;

          NOW THEREFORE, in consideration of the premises and the mutual
covenants, and in reliance on the representations and warranties, contained or
incorporated by reference in this Agreement, the parties agree as follows:

          SECTION 1.  Issuance and Transfer of the Shares. The Company agrees to
                      -----------------------------------
issue and sell to the Purchaser, and the Purchaser hereby agrees to purchase
from the Company, the number of Shares set forth opposite the name of the
Purchaser under the heading "Number of Shares to be Purchased" on Schedule I, at
                                                                  ----------
the aggregate purchase price set forth opposite the name of the Purchaser under
the heading "Aggregate Purchase Price for Shares" on Schedule I.
                                                     ----------

          SECTION 2.  Representations and Warranties of the Company.
                      ---------------------------------------------

          (a)  The Company is a corporation duly incorporated, validly existing
and in good standing under the laws of the State of Delaware and is duly
licensed or qualified to transact business as a foreign corporation in the
Commonwealth of Pennsylvania.  The Company has the corporate power and authority
to execute, deliver and perform this Agreement and to issue and deliver the
Shares.

          (b)  The execution and delivery by the Company of this Agreement, the
performance by the Company of its obligations hereunder and the issuance and
delivery of the Shares have been duly authorized by all requisite corporate
action.

          (c)  The Shares have been duly authorized and, when issued in
accordance with this Agreement, will be validly issued, fully paid and
nonassessable shares of Common Stock with no personal liability attaching to the
ownership thereof and will be free and clear of all liens, charges,
restrictions, claims and encumbrances imposed by or through the Company.

<PAGE>

          (d)  This Agreement has been duly executed and delivered by the
Company and constitutes the legal, valid and binding obligation of the Company,
enforceable in accordance with its terms.

          (e)  The capitalization of the Company immediately following the
issuance and delivery of the Shares will be as set forth on Exhibit A hereto.
                                                            ---------

          (f)  The Certificate of Incorporation of the Company is as set forth
on Exhibit B hereto, is in full force and effect, and has not been restated or
   ---------
amended since the date thereof.

          (g)  The representations and warranties of the Company set forth in
Article II of the Series A Convertible Preferred Stock Purchase Agreement dated
as of March 15, 1996 (the "Preferred Stock Purchase Agreement") by and among the
Company and the several purchasers named in Schedule I attached thereto
(including the qualifications set forth in Section 2.10 thereof) are
incorporated by reference herein and made a part hereof as if fully set forth
herein (with references to "this Agreement" being deemed to refer to the
Preferred Stock Purchase Agreement).

          SECTION 3.  Representations and Warranties of the Purchaser.  The
                      -----------------------------------------------
Purchaser represents and warrants to the Company that:

          (a)  it is an "accredited investor" within the meaning of Rule 501(a)
of Regulation D as promulgated under the Securities Act and was not organized
for the specific purpose of acquiring the Shares;

          (b)  it has sufficient knowledge and experience in investing in
companies similar to the Company in terms of the Company's stage of development,
i.e. start-up or development stage enterprises with very limited operating
history and no net income from operations to date, so as to be able to evaluate
the risks and merits of its investment in the Company and it is able financially
to bear the risks thereof;

          (c)  it has had an opportunity to discuss the Company's business,
management and financial affairs with the Company's management and the Company
has furnished to it all information which it considers necessary to form a
decision concerning the acquisition of the Shares and no valid request to the
Company for such information has been refused or denied by the Company or
remains unfilled as of the date hereof;

          (d)  it is acquiring the Shares for its own account for the purpose of
investment and not with a view to any resale or distribution thereof, in whole
or in part, in violation of the Securities Act of 1933, as amended (the "Act");

          (e)  it understands that (i) the Shares have not been registered under
the Act, based and in reliance upon such Purchaser's representations, warranties
and agreements

                                       2
<PAGE>

as set forth herein and are being issued and sold pursuant hereto. in a
transaction exempt from the registration requirements of the Act pursuant to
Section 4(2) thereof, (ii) the Shares must be held indefinitely unless a
subsequent disposition thereof is registered under the Act or is exempt from
such registration, (iii) the Shares are "restricted securities" as that term is
defined in Rule 144 of the General Rules and Regulations under the Act, (iv) the
Shares will bear a legend substantially to the effect as set forth in clauses
(ii) and (iii) above, (v) the Company will make a notation on its transfer books
to such effect and (vi) the Shares represent a speculative investment involving
a very high degree of risk, are highly illiquid. have no public market and that
it is not likely that a public market for the Shares will develop;

          (f)  it understands that any routine sales of the Shares in reliance
upon Rule 144 under the Act, if the provisions of such Rule should then be
available as to the Shares, can be made only after the holding period specified
in the Rule, and in accordance with all the terms and conditions of that Rule
and that, in the case of securities to which that Rule is not applicable,
compliance with Regulation A under the Act or some other exemption under the Act
will be required; it further understands that Rule 144 is not now available for
the resale of the Shares and that the Company may, if it so desires, permit the
transfer of the Shares only when such Shares are the subject of an effective
registration statement under the Act or when the Company has received an opinion
of counsel, in form acceptable to the Company, that such registration is not
required under the Act, and it agrees to furnish such documentation and
undertakings as the Company and its counsel may reasonably require in connection
with any such opinion prior to such counsel's giving or approving any such
opinion;

          (g)  if it sells any Shares pursuant to Rule 144A promulgated under
the Act, it will take all necessary steps in order to perfect the exemption from
registration provided thereby, including (i) obtaining on behalf of the Company
information to enable the Company to establish a reasonable belief that the
purchaser is a "qualified institutional buyer" as such term is defined in Rule
144A and (ii) advising such purchaser that Rule 144A is being relied upon with
respect to such resale;

          (h)  it understands that the Company is the only person which may
register its securities under the Act and that the Company is currently not
contemplating registration of any of its Common Stock;

          (i)  the Company has not made any representations, warranties or
covenants to the Purchaser regarding the registration of the Shares or
compliance with Regulation A or any other exemption under the Act, except as set
forth in that certain Registration Rights Agreement dated as of event date
herewith by and among the Company and the stockholders of the Company named
therein (including the Purchaser);

                                       3
<PAGE>

          (j)  the Purchaser is a corporation duly incorporated, validly
existing and in good standing under the laws of the State of New York; and the
Purchaser has the corporate power and authority to execute, deliver and perform
this Agreement;

          (k)  the execution and delivery by the Purchaser of this Agreement and
the performance by the Purchaser of its obligations hereunder have been duly
authorized by all requisite corporate action; and

          (l)  the foregoing representations and warranties and all other
information about it provided to the Company are true and accurate as of the
date hereof and such representations and warranties shall survive the transfer
of the Shares to the Purchaser.

          SECTION 4.  Covenants of the Company.
                      ------------------------

          (a)  The Purchaser hereby acknowledges that the securities issued by
the Company in connection with an equity financing may bear special rights and
preferences under the Company's Certificate of Incorporation which are different
from and superior to the rights that attach to the Shares and that the Company
shall have no obligation to grant the Purchaser, as a holder of Shares, any of
such special rights and preferences.

          (b)  Notwithstanding the proviso in Section 4(a) above, if at any time
prior to the Company's initial public offering of its equity securities pursuant
to a registration statement declared effective pursuant to the Act (except
registrations on Forms S-4 or S-8 or any successor forms thereto) (a "Public
Offering"), the Company proposes to offer any shares of its equity securities
other than (i) shares issuable upon conversion of convertible securities of the
Company outstanding from time to time, (ii) shares issued to officers, directors
or employees of, consultants to, or members of the Scientific Advisory Board of,
the Company pursuant to stock option or stock purchase plans or agreements on
terms approved by the Board of Directors of the Company, (iii) shares excluded
from the definition of "Additional Shares of Common Stock" as described in
Article Fourth, Section C4(d)(i)(4)(A),(B) and (C) of the Company's Certificate
of Incorporation, (iv) shares issued pursuant to stock splits, stock dividends
and the like, (v) shares offered to the public pursuant to an underwritten
Public Offering and (vi) shares issued in connection with a bona-fide strategic
business arrangement or lease arrangement in which the person or entity
receiving such shares or an affiliate of such person or entity (which in either
case is not a stockholder of any of the Company's equity securities or an
affiliate of a stockholder of any of the Company's equity securities) enters
into a contractual relationship with the Company related to research and
development, manufacturing, marketing, licensing or leasing, which issuance and
transaction are approved in good faith by the Board, the Company will first
offer to each Purchaser a percentage of such shares (the "Offered Shares") equal
to such Purchaser's percentage ownership of the Common Stock of the Company
(calculated on a fully-diluted basis), in the following manner:

                                       4
<PAGE>

                    (1) The Company shall promptly deliver a notice ("Notice")
to the Purchaser stating: (i) the Company's bona fide intention to sell such
equity securities, (ii) the number of shares of equity securities proposed to be
sold, (iii) the number of shares of equity which the Purchaser is entitled to
purchase, (iv) the price for which it proposes to sell such equity securities
and (v) any other material terms of the sale.

                    (2) Within twenty (20) days after the receipt by Purchaser
of such Notice or attempted delivery during working hours to its address shown
on the books of the Company (such date is referred to as the "Receipt Date"),
the Purchaser may, by delivering a written notice (the "Reply") to the Company
before the close of business on the twentieth (20th) day following the Receipt
Date, elect to purchase, at the price and on the terms specified in the Notice,
up to that number of shares representing a percentage of such equity securities
equal to the Purchaser's then fully-diluted percentage ownership of the Company.
The exact number of shares of equity securities desired to be purchased shall be
set forth in the Reply.

                    (3) During the ninety- (90-) day period following the period
required in clause (2) above, the Company may sell up to the number of shares of
equity securities not elected to be purchased as provided in clause (2) above,
at the price specified in the Notice or at a higher price and on substantially
the same terms or less favorable terms to the purchasers thereof.

          SECTION 5.  Covenants of the Purchaser.
                      --------------------------

          (a)  Right of First Refusal. (i) If at any time the Purchaser desires
               ----------------------
to sell all or any part of the Shares pursuant to a bona fide offer from a third
party (the "Proposed Buyer"), the Purchaser shall submit a written offer (the
"Offer'') to sell such Shares (the "Offered Shares") to the Company on terms and
conditions, including price, not less favorable to the Company than those on
which the Purchaser proposes to sell the Offered Shares to the Proposed Buyer.
The Offer shall disclose the identity of the Proposed Buyer, the Offered Shares
proposed to be sold, the total number of Shares then owned by the Purchaser, the
terms and conditions, including price, of the proposed sale, and any other
material facts relating to the proposed sale. The Offer shall further state that
the Company may acquire, in accordance with the provisions of this Agreement,
all or any portion of the Offered Shares for the price and upon the other terms
and conditions, including deferred payment (if applicable), set forth therein.

          (ii) If the Company desires to purchase all or any part of the
Offered Shares, the Company shall communicate in writing its election to
purchase to the Purchaser, which communication shall state the number of Offered
Shares the Company desires to purchase and shall be given to the Purchaser
within thirty (30) days of the date the Offer was made. Such communication
shall, when taken in conjunction with the

                                       5
<PAGE>

Offer, be deemed to constitute a valid, legally binding and enforceable
agreement for the sale and purchase of such Offered Shares. Sales of the Offered
Shares to be sold to the Company pursuant to this Section 5(a) shall be made at
the offices of the Company on the 45th day following the date the Offer was made
(or if such 45th day is not a business day, then on the next succeeding business
day). Such sales shall be effected by the Purchaser's delivery to the Company of
a certificate or certificates evidencing the Offered Shares to be purchased by
it, duly endorsed for transfer to the Company, against payment to the Purchaser
of the purchase price therefor by the Company.

          (iii)  If the Company does not purchase all of the Offered Shares, the
Offered Shares not so purchased may be sold by the Purchaser at any time within
six months after the date the Offer was made, subject to the other provisions of
this Agreement. Any such sale shall be to the Proposed Buyer, at not less than
the price and upon other terms and conditions, if any, not more favorable to the
Proposed Buyer than those specified in the Offer. Any Offered Shares not sold
within such six-month period shall continue to be subject to the requirements of
this Section 5(a).

          (b)  The Company and the Purchaser agree that until the initial Public
Offering of any of the Company's capital stock, (i) the Shares may not be sold,
pledged or otherwise transferred by the Purchaser to any person which the
Company reasonably believes to be a competitor of the Company, and (ii) any
purchaser of the Shares shall, as a condition to the effectiveness of such
transfer, agree in writing with the Company to the restrictions on the transfer
of the Shares set forth in Section 5(a).

          (c)  This Section 5 shall not apply to any sale by the Purchaser as
part of an initial Public Offering of any of the Company's capital stock, and
this Section 5 shall terminate and be of no further force or effect
automatically upon consummation of such initial Public Offering.

          SECTION 6.  Miscellaneous.
                      -------------

          (a)  Survival of Agreements.  All covenants, agreements,
               ----------------------
representations and warranties made herein or in any instrument delivered to
either party pursuant to or in connection with this Agreement, shall survive the
execution and delivery of this Agreement.

          (b)  Parties in Interest.  All representations, covenants and
               -------------------
agreements contained in this Agreement by or on behalf of either of the parties
hereto shall bind and inure to the benefit of the respective successors and
permitted assigns of such party whether so expressed or not.

          (c)  Notices.  All notices, requests, consents and other
               -------
communications hereunder shall be in writing and shall be delivered in person,
mailed by certified or

                                       6
<PAGE>

registered mail, return receipt requested, or sent by telecopier or telex,
addressed as follows:

               (i)  if to the Company; c/o Falcon Technology Partners, L.P.,
James L. Rathmann, President, 600 Dorset Road, Devon, PA 19333 (Facsimile No.:
(610) 688-2571).

          and

               (ii) if to the Purchaser, the addresses set forth on Schedule I;
                                                                    ----------

or, in any such case, at such other address or addresses as shall have been
furnished in writing by such party to the other.

          (d)  Governing Law.  This Agreement shall be governed by and construed
               -------------
in accordance with the laws of the State of Delaware (without giving effect to
its conflicts of laws principles).

          (e)  Entire Agreement.  This Agreement, together with the other
               ----------------
agreements referred to herein, constitute the entire agreement of the parties
with respect to the subject matter hereof and thereof.

          (f)  Counterparts.  This Agreement may be executed in two or more
               ------------
counterparts, each of which shall be deemed an original, but all of which
together shall constitute one and the same instrument.

          (g)  Amendments.  This Agreement may not be amended or modified
               ----------
without the written consent of the Company and the Purchaser, and no provisions
hereof may be waived without the written consent of the party in favor of which
such provision would operate without such waiver.

          (h)  Severability.  If any provision of this Agreement shall be
               ------------
declared void or unenforceable by any judicial or administrative authority, the
validity of any other provision and of the entire Agreement shall not be
affected thereby.

          (i)  Titles and Subtitles.  The titles and subtitles used in this
               --------------------
Agreement are for convenience only and are not to be considered in construing or
interpreting any term or provision of this Agreement.

             [THE REMAINDER OF THIS PAGE LEFT INTENTIONALLY BLANK]

                                       7
<PAGE>

IN WITNESS WHEREOF, the Company and the Purchaser have executed this Agreement
as of the day and year first above written.

GENOMICA CORPORATION

By:

/s/ James L. Rathmann
----------------------------------
James L. Rathmann
President

PURCHASER:

By:

----------------------------------

                                       8
<PAGE>

                                  SCHEDULE I
                                  ----------

Purchaser                               Number of Shares      Aggregate Purchase
---------                               ----------------      ------------------
                                        To Be Purchased       Price for Shares
                                        ----------------      ----------------

                                       9
<PAGE>

                                   Exhibit A

           Genomica Corporation Capitalization Table              March 22, 1996

<TABLE>
<CAPTION>
                                       Common Stock  % of Common   Series A Preferred  % Series A   Total Shares   % of Total
<S>                                    <C>           <C>           <C>                 <C>          <C>            <C>
Falcon Technology Partners L.P.                                             1,660,200       50.00%     1,660,200       26.06%
Rathmann Family                             600,000        19.67%                                        600,000        9.42%
Harris and Harris Group, Inc.               199,800         6.55%           1,660,200       50.00%     1,860,000       29.20%
Cold Spring Harbor Laboratory               679,679        22.29%                                        679,697       10.67%
John Maroney                                 60,121         1.97%                                         60,121        0.94%
Thomas Marr                               1,080,000        35.41%                                      1,080,000       16.95%
Donald Fisher                               250,000         8.20%                                        250,000        3.92%
Jackie Salit                                 30,000         0.98%                                         30,000        0.47%
Steve Cozza                                  30,000         0.98%                                         30,000        0.47%
Pool for inventions                         120,000         3.93%                                        120,000        1.88%

Total                                     3,049,600       100.00%           3,320,400      100.00%     6,370,000      100.00%
</TABLE>

<PAGE>

                      Common Stock Acquisition Agreements
                      -----------------------------------

                             Supplemental Schedule
                             ---------------------

The following investors executed Common Stock Acquisition Agreements with the
Company:

Investor                                      Number of Shares
-------                                       ----------------

Thomas Marr                                   1,080,000

Harris and Harris Group, Inc.                 199,800

James L. Rathmann                             600,000
Margaret C. Rathmann
Laura Jean Rathmann
Sally A. Rathmann
Richard G. Rathmann

Cold Spring Harbor Laboratory                 679,679

John Maroney                                  60,121

Jacqueline Salit                              30,000

Steven Cozza                                  30,000

Donald Fisher                                 250,000

                                       12<PAGE>

                                                                    EXHIBIT 10.2

                             GENOMICA CORPORATION
                            STOCKHOLDERS AGREEMENT

     THIS AGREEMENT is made as of the 22th day of March, 1996, by and among
Genomica Corporation, a Delaware corporation, (the "Corporation"); Cold Spring
Harbor Laboratory ("CSH"); and the persons (the "Purchasers") named in Schedule
I to a certain Series A Convertible Preferred Stock Purchase Agreement of the
Corporation dated the date hereof (the "Purchase Agreement").

                                   RECITALS
                                   --------

     The Corporation is engaged in the highly competitive business of
researching, developing, manufacturing and marketing computer software for the
biotechnology industry on an international basis. The CSH and the Corporation
recognize and affirm that success or failure in this highly technical and highly
competitive business is dependent on the ability of the Corporation to (1)
develop and protect proprietary technology which will give the Corporation a
competitive advantage in the marketplace; (2) incorporate this technology into
products which themselves will or may become proprietary; and (3) develop and
utilize processes which may be proprietary to accomplish (1) and (2) above.

     In order to achieve the above objectives, the Corporation has expended and
will continue to expend substantial time, effort and financial resources.  These
activities include research, the attraction and training of key employees, and
establishing relationships with necessary resources outside the Corporation.  If
information regarding the Corporation's research, processes or products were to
fall into the hands of a competitor of the Corporation, it could be used in a
manner which would cause serious and irreparable financial and business damage
to the Corporation. For this reason, all information related to the
Corporation's technology, research, products, and business strategies is
considered to be confidential information which is proprietary to the
Corporation.

     In addition the Purchasers intend to invest in the Corporation pursuant to
the Purchase Agreement based on the foregoing assumptions and such investment is
contingent upon the execution and delivery of this Agreement by the Corporation
and CSH.

                                   AGREEMENT
                                   ---------

     NOW, THEREFORE, in consideration of the above representations and
understandings, and the promises and mutual agreements set forth below, the
parties agree, effective on the date of the Agreement, to the following terms
and conditions:
<PAGE>

     1.  CSH's Stock.  CSH has purchased from the Corporation an aggregate of
679,679 shares of Common Stock (the "Shares") at a per-share purchase price of
$.001 (the "Original Purchase Price") as more specifically set forth on Schedule
1 hereto.  The Shares shall be subject to a number of restrictions as set forth
in this Agreement. Certain of the restrictions with respect to the Shares may
terminate under various conditions pursuant hereto.

     2.  Remedies in the Event of Breach.  The Corporation, the Purchasers and
CSH understand and agree that any breach or threatened breach by the
Corporation, the Purchasers or CSH of any of the provisions hereof cannot be
remedied solely by the recovery of damages, and in the event of any such breach
or threatened breach, the Corporation, the Purchasers or CSH, as the case may
be, shall be entitled to injunctive relief, restraining CSH, the Purchasers or
the Corporation, as the case may be, and any business, firm, corporation
individual or other entity participating in such breach or attempted breach,
from engaging in any activity which would constitute a breach.  The Corporation,
the Purchasers and CSH further agree that any dispute arising under the terms of
this Agreement shall be decided in accordance with the rules then in effect of
the American Arbitration Association, and any arbitration award may be entered
in a court of competent jurisdiction and enforced as a judgment thereof. Nothing
herein, however, shall be construed as (i) prohibiting the Corporation, the
Purchasers or CSH from pursuing, in conjunction with an injunction or otherwise,
any other remedies available in equity or at law for any such breach or
threatened breach, including the recovery of damages; or (ii) limiting the
Corporation's remedy against a breaching Purchaser or CSH as set forth in
Section 9 below.

     3.  Transferability.  The Corporation and CSH agree (i) that Unvested
Shares (as defined below) may not be sold, pledged or otherwise transferred
("Transferred") without the consent of the Board of Directors in its sole
discretion (except pursuant to Section 5 below); and (ii) Vested Shares (as
defined below) may be Transferred only in accordance with the provisions set
forth herein and only if the transferee of such Vested Shares agrees in writing
to be bound by the provisions of Sections 5, 6, 7, 9 and 10 hereof.  Any Shares
Transferred not in accordance with the preceding sentence shall be void, ab
initio.

     4.  Discontinuation Event.  The Shares shall be affected as follows:

     (A) In the event (i) the dissolution, liquidation or bankruptcy of CSH; or
(ii) of a breach by CSH of any of the material terms of any of the License
Agreement (which breach shall have been a material breach and shall not have
been cured prior to the expiration of any cure period) or the Common Stock
Acquisition Agreement by which CSH purchased the Shares (either such case, a
"Discontinuation Event"), certain of such Shares, defined below as "Unvested
Shares," shall be repurchased and paid for in full by the Corporation at the
Original Purchase Price within 30 days of such Discontinuation

                                       2
<PAGE>

Event. Unvested Shares shall be those Shares which have not yet vested according
to the schedule set forth in Schedule 1 hereto. Notwithstanding the preceding
sentence, in the event the Corporation's Board of Directors approves a sale or
merger (other than a merger with or into a wholly-owned subsidiary of the
Corporation or a merger in which the Corporation is the surviving entity) of the
Corporation or an initial public offering of the Corporation's stock (any of
which events is defined herein as a "Triggering Transaction"), CSH will be
notified of such Board action. Any of such then Unvested Shares will become
Vested Shares (as defined below) simultaneously with the consummation of the
Triggering Transaction. Upon the occurrence of a Discontinuation Event, all
Unvested Shares shall forever remain Unvested Shares.

     (B) Termination For Cause.  Prior to the Corporation's initial public
offering, in the event of a Discontinuation Event as a result of an event set
forth in clause (ii) of Section 4(A) above, then with respect to any of its
Unvested Shares not repurchased by the Corporation pursuant to Sections 4(A)
above, CSH shall, in all matters put forth to a vote of the holders of Common
Stock (i) cause its Shares to be represented at any meeting of the stockholders
of the Corporation and (ii) vote such Shares in the same proportion and in the
same manner as all other Common Stock is voted.

     5.  Approved Sale of Corporation.  (A) If the Corporation's Board of
Directors has adopted a resolution of the Board of Directors approving the sale
of the Corporation to any person (such person, the "Acquiring Entity"), whether
by merger, consolidation, sale of all or substantially all of the Corporation's
assets or sale of all of the outstanding capital stock (such sale, an "Approved
Sale"), CSH and each Purchaser will consent to, vote for and raise no objections
against the Approved Sale, and if the Approved Sale is structured as a sale of
stock, CSH and each Purchaser hereby agrees to sell all of their respective
Shares (and all rights thereto) on the terms and conditions approved by the
Board of Directors, provided that each holder of Common Stock receives in the
Approved Sale the same amount and type of consideration for is interest in the
Corporation as is received by the holders of the Series A Convertible Preferred
Stock, (the "Preferred Stock"), assuming such holders had converted their
respective shares of Preferred Stock into Common Stock.  CSH and each Purchaser
will take all actions reasonably required to facilitate and consummate an
Approved Sale of the Corporation.

     (B) The Corporation shall give written notice (a "Sale Notice") of any such
Approved Sale to CSH and Purchasers.  A Sale Notice shall contain (i) the name
and address of the prospective Acquiring Entity; (ii) the purchase price and
other material terms and conditions of the Approved Sale; (iii) the date on
which the Approved Sale is intended to be consummated; (iv) the date on which
the Corporation's Board of Directors approved the Approved Sale and (v) the
Shares and Purchaser's Shares proposed to be sold.  Upon receipt of a Sale
Notice, CSH and each Purchaser shall be required to consent to such Approved
Sale and to sell is Shares, to the Acquiring Entity designated therein within 30
days of receipt thereof or such later date as may be specified in the Sale
Notice.

                                       3
<PAGE>

No Purchaser or CSH shall be required to make any representations and warranties
other than representations and warranties concerning its ownership of such
Shares, the absence of any liens or encumbrances thereon and its authority to
sell such Shares; and provided further that, if the terms of such Approved Sale
provide for the escrow of any amount of proceeds resulting from an Approved Sale
or to accept indebtedness or other securities subject to indemnification or
other rights of offset, then CSH and each Purchaser shall be required to escrow
a pro rata amount of its proceeds from such Approved Sale and/or to accept such
indebtedness or other securities.

     6.  Right of First Refusal.  (A) Except pursuant to Section 5 above, if at
any time CSH desires to sell for cash all or any part of its Shares pursuant to
a bona fide offer from a third party (the "Proposed Transferee"), CSH shall
submit a written offer (the "Offer") to sell such Shares (the "Offered Shares")
to the Purchasers on terms and conditions, including price, not less favorable
to the Purchasers than those on which CSH proposes to sell such Offered Shares
to the Proposed Transferee. The Offer shall disclose the identity of the
Proposed Transferee, the Offered Shares proposed to be sold, the total number of
Shares owned by CSH, the terms and conditions, including price, of the proposed
sale, that the proposed buyer has been informed of the rights and obligations
provided for in this Section 6 and Section 7 below and has agreed to purchase
Offered Shares in accordance with the terms of this Agreement, and any other
material facts relating to the proposed sale. The Offer shall further state that
the Purchasers may acquire, in accordance with the provisions of this Agreement,
all but not less than all of the Offered Shares for the price and upon the other
terms and conditions, including deferred payment (if applicable), set forth
therein.

     (B) Each Purchaser shall have the absolute right to purchase that number of
Offered Shares as shall be equal to the number of Offered Shares multiplied by a
fraction, the numerator of which shall be the number of Purchasers' Shares (as
defined below) then owned by such Purchaser and the denominator of which shall
be the aggregate number of Purchasers' Shares then owned by all of the
Purchasers. For purposes of this Section 6, all of the securities of the
Corporation which a Purchaser has acquired, or has the right to acquire from the
Corporation, upon the conversion, exercise or exchange of any of the securities
of the Corporation then owned by such Purchaser shall be deemed to be
Purchasers' Shares then owned by such Purchaser. (The amount of Offered Shares
that each Purchaser is entitled to purchase under this Section 6(B) shall be
referred to as its "Pro Rata Fraction").

     (C) The Purchasers shall have a right of oversubscription such that if any
Purchaser fails to accept the Offer as to its Pro Rata Fraction, the other
Purchasers shall, among them, have the right to purchase up to the balance of
the Offered Shares not so purchased. Such right of oversubscription may be
exercised by a Purchaser by accepting the Offer as to more than its Pro Rata
Fraction. If, as a result thereof, such oversubscriptions exceed the total
number of Offered Shares available in respect of such

                                       4
<PAGE>

oversubscription privilege, the oversubscribing Purchasers shall be cut back
with respect to their oversubscriptions on a pro rata basis in accordance with
their respective Pro Rata Fractions or as they may otherwise agree among
themselves. In the event that the Purchasers in the aggregate shall not have
elected in the manner set forth below to purchase all of the Offered Shares, the
Purchasers shall not have the right to purchase any of the Offered Shares and
CSH shall have the right to sell the Offered Shares in accordance with Section
6(E) below.

     (D) If the Purchasers, in the aggregate, desire to purchase all of the
Offered Shares, such Purchaser(s) shall communicate in writing their election to
purchase to CSH, which communication shall state the number of Offered Shares
each Purchaser desires to purchase (which shall in the aggregate be equal to all
the Offered Shares) and shall be given to CSH within thirty days of the date the
Offer was made. Such communication shall, when taken in conjunction with the
Offer, be deemed to constitute a valid, legally binding and enforceable
agreement for the sale and purchase of such Offered Shares (subject to the
aforesaid limitations as to a Purchaser's right to purchase more than its Pro
Rata Fraction). Sales of the Offered Shares to be sold to purchasing Purchasers
pursuant to this Section 6 shall be made at the offices of the Corporation on
the 45th day following the date the Offer was made (or if such 45th day is not a
business day, then on the next succeeding business day). Such sales shall be
effected by CSH's delivery to each purchasing Purchaser of a certificate or
certificates evidencing the Offered Shares to be purchased by it, free and clear
of any liens, claims or encumbrances of any kind (other than pursuant to this
Agreement), duly endorsed for transfer to such purchasing Purchaser and with any
requisite stock transfer stamps attached, against payment to CSH of the purchase
price therefor by such purchasing Purchaser.

     (E) If the Purchasers do not purchase all of the Offered Shares, the
Offered Shares may be sold by CSH at any time within six months after the date
the Offer was made, subject to Section 7 below and the other provisions of this
Agreement. Any such sale shall be to the Proposed Transferee, at not less than
the price and upon other terms and conditions, if any, not more favorable to the
Proposed Transferee than those specified in the Offer. Any Offered Shares not
sold within such six-month period shall continue to be subject to the
requirements of a prior offer pursuant to this Section 6.

     7.  Co-Sale Rights.  (A) If at any time a Purchaser desires to sell all or
any part of its Common Stock or Preferred Stock ("Purchaser's Shares") pursuant
to a bona fide offer from a third party (for purposes of this Section 7, also a
"Proposed Transferee"), such Purchaser shall deliver a written notice (the
"Notice") of such proposed sale of such Purchaser's Shares (for purposes of this
Section 7, also "Offered Shares") to the other Purchaser. The Notice shall
disclose the identity of the Proposed Transferee, the Offered Shares proposed to
be sold, the total number of Purchaser's Shares owned by such Purchaser, the
terms and conditions, including price, of the proposed sale, that the proposed
buyer has been informed of the rights and obligations provided for in this

                                       5
<PAGE>

Section 7 and has agreed to purchase Offered Shares in accordance with the terms
of this Agreement, and any other material facts relating to the proposed sale.

     (B) (i) If a Purchaser elects not to purchase any Offered Shares pursuant
to Section 6 above; or (ii) if upon receipt of a Notice pursuant to Section 7(A)
above, such Purchaser desires to sell any of such Purchaser's Shares, then such
Purchaser shall have the right, exercisable upon written notice (the "Co-Sale
Acceptance Notice'') to the selling Purchaser or CSH, as applicable, given
within thirty (30) days after the Offer or Notice, as applicable has been
delivered pursuant to Section 6 or 7(A) above, to participate in the proposed
sale of Offered Shares pursuant to the terms and conditions specified in the
Offer or Notice, as applicable, and the selling Purchaser or CSH, as applicable,
shall require the Proposed Transferee designated in the Offer or Notice, as
applicable, to purchase from such Purchaser up to the number of whole shares of
Common Stock or Preferred Stock, as applicable, equal to the product of (i) the
total number of Offered Shares to be transferred in such proposed sale as
specified in the Offer or Notice, as applicable, and (ii) a fraction, the
numerator of which (a) in the case of Offered Shares which are Common Stock, is
the number of outstanding shares of Common Stock held by such Purchaser
(including any Common Stock issuable to such Purchaser upon the conversion or
exchange of any Purchaser's Shares convertible or exchangeable into Common
Stock) or (b) in the case of Offered Shares which are Preferred Stock, is the
number of outstanding shares of Preferred Stock held by such Purchaser, and the
denominator of which (c) in the case of Offered Shares which are Common Stock,
is the total number of shares of Common Stock (on a fully-diluted basis) then
outstanding or (d) in the case of Offered Shares which are Preferred Stock, is
the total number of shares of Preferred Stock (on a fully-diluted basis) then
outstanding. The Co-Sale Acceptance Notice shall state the number of shares such
Purchaser proposes to include in such proposed sale to the Proposed Transferee
(up to the number of shares as calculated pursuant to the immediately preceding
sentence). Any such sale by such Purchaser shall be at the same price per share
(including price and type of consideration) received by the Proposed Transferee
and otherwise on identical terms and conditions as received by the selling
Purchaser or CSH, as the case may be, in its sale to the Proposed Transferee. In
the event that the Proposed Transferee does not purchase shares of Common Stock
and/or Preferred Stock from Purchasers who have timely delivered a Co-Sale
Acceptance Notice as required by this Section 7, then the selling Purchaser or
CSH, as the case may be, shall not be permitted to, and shall not, sell any
Offered Shares to the Proposed Transferee in the proposed sale.

     (C) If no Co-Sale Acceptance Notice is received by the selling Purchaser or
CSH, as the case may be, during the 30-day period referred to in Section 7(A)
above, then such selling Purchaser or CSH, as the case may be, shall have the
right to sell the Offered Shares at any time within six months after the date
the Offer or Notice, as the case may be was delivered, subject to the other
provisions of this Agreement.  Any such sale shall be to the Proposed
Transferee, at not less than the price and upon other terms

                                       6
<PAGE>

and conditions, if any, not more favorable to the Proposed Transferee than those
specified in the Offer or Notice, as applicable. Any Offered Shares not sold
within such six-month period shall continue to be subject to the requirements of
Section 6 and this Section 7.

     (D) In the event a Purchaser shall desire to sell more than 50% of all of
such Purchaser's Shares purchased pursuant to the Purchase Agreement in the
aggregate in one or a series of related transactions to a Proposed Transferee,
such Purchaser shall in addition to offering the Co-Sale rights to the other
Purchaser pursuant to Sections 7(A) through (C), such Purchaser shall offer such
rights to CSH as if CSH were a Purchaser for purposes of such Sections. In the
event a Purchaser proposes to sell Preferred Stock, the number of shares of
Common Stock which CSH shall be entitled to sell shall be calculated as if all
shares of Preferred Stock were converted into Common Stock at the then
applicable conversion price and the purchase price per share of Common Stock to
be sold by CSH pursuant to this Section 11(D) shall equal the aggregate purchase
price paid for the shares of Preferred Stock sold by such Purchaser to the
Proposed Transferee divided by the number of shares of Common Stock into which
such shares of Preferred Stock were convertible at the time of such sale at the
then applicable conversion price.

     (E) Notwithstanding the foregoing, this Section 7 shall not apply to any
Transfer by any Purchaser or CSH of Shares: (i) to Purchaser's or CSH's
affiliates, (ii) constituting a gift or gifts, or (iii) constituting less than
1% of the outstanding class of Shares to be Transferred.

     8.  Termination.  The provisions of Sections 3, 4, 5, 6 and 7 hereof, shall
terminate immediately upon the closing of a firm commitment, underwritten public
offering registered under the Securities Act, (other than a registration
relating solely to a transaction referred to in Rue 145 under the Securities Act
(or any successor rule) or to an employee benefit plan of the Corporation), at a
public offering price (prior to underwriters' discounts and expenses) equal to
or exceeding $2.50 per share of Common Stock (as adjusted for any stock
dividends, combinations or splits with respect to such shares) and in which the
aggregate proceeds to the Corporation and/or selling stockholders (before
deduction for underwriters' discounts and expenses relating to the issuance,
including without limitation fees of the Corporation's counsel) exceed
$5,000,000.

     9.  Failure to Deliver Shares.  CSH becomes obligated to sell any Shares to
a Purchaser or the Corporation under this Agreement and fails to deliver such
Shares in accordance with the terms of this Agreement, such Purchaser or the
Corporation, as the case may be, may, at its option, in addition to all other
remedies it may have, send to CSH the purchase price for such Shares as is
herein specified. Thereupon, the Corporation upon written notice to CSH, (i)
shall cancel on its books the certificate or certificates representing the
Shares to be sold and (ii) shall issue, in lieu thereof, in the name of such
Purchaser or the Corporation, as the case may be, a new certificate or

                                       7
<PAGE>

certificates representing such Shares, and thereupon all of CSH's rights in and
to such Shares shall terminate.

     10.  Lock-up.  If requested by the underwriters for the initial
underwritten public offering of securities of the Corporation, CSH and each
Purchaser shall agree not to sell, assign, transfer, pledge, hypothecate,
mortgage, encumber or otherwise dispose of all or any of such Shares, without
the written consent of such underwriters, for a period of not more than 180 days
following the effective date of the registration statement relating to such
offering. This Section 10 shall expressly survive the termination of this
Agreement.

     11.  No Waiver.  Any waiver of a breach of any of the terms of this
Agreement shall not operate as a waiver of any other breach of such terms or
conditions or any other terms or conditions, nor shall any failure to enforce
any provision of this Agreement operate as a waiver of such provision or any
other provision.

     12.  Successors and Assigns.  The rights, benefits and obligations of the
Corporation under this Agreement and all covenants and agreements hereunder
shall inure to the benefit of and be enforceable by or against its successors
and assigns.  Subject to the limitations set forth herein, this Agreement shall
inure to the benefit of and be binding upon the successors and assigns of CSH.
Subject to the limitations set forth herein, neither this Agreement nor any
rights or obligations hereunder shall be assigned by CSH.  The rights and
obligations of the Purchasers hereunder shall inure to the benefit of and be
binding upon the Purchasers respective successors and assigns.

     13.  Entire Agreement.  The Agreement (with respect to the Corporation and
the Purchasers, together with the Purchase Agreement), constitutes the entire
agreement among the parties.  This Agreement may not be amended or modified,
except in writing, and signed by each of the Purchasers and CSH.

     14.  Severability.  If any provision of this Agreement or the application
thereof is held invalid or unenforceable, the invalidity or unenforceability
thereof shall not affect any other provisions or applications of this Agreement
which can be given effect without the invalid or unenforceable provision or
application. To that end, the provisions of this Agreement are to be severable.

     15.  Governing Law.  This Agreement shall be governed by and construed in
accordance with the internal laws of the State of New York (without giving
effect to its conflicts of laws principles).

                 [REMAINDER OF PAGE INTENTIONALLY LEFT BLANK]

                                       8
<PAGE>

     IN WITNESS WHEREOF, the Corporation has caused this Agreement to be signed
and each of CSH and the Purchasers have executed this Agreement as of the date
shown below.

                                        GENOMICA CORPORATION

Dated:__________, 1996          BY:______________________________
                                TITLE:___________________________
Dated:__________, 1996

                                        COLD SPRING HARBOR LABORATORY

                                        BY:/s/ John Maroney
                                           -------------------------------------
                                        TITLE:__________________________________
                                               John Maroney
                                               Assistant Administrative Director
                                        PURCHASERS:

                                        FALCON TECHNOLOGY PARTNERS, L.P.,
                                            a Delaware limited partnership

                                        BY:/s/ James L. Rathmann
                                           -------------------------------------
                                        TITLE: General Partner

                                        HARRIS & HARRIS GROUP, INC.,
                                            a Delaware corporation

                                        BY:/s/
                                           -------------------------------------
                                        TITLE: Executive Vice President
                                              ----------------------------------

                                       9
<PAGE>

                                  SCHEDULE 1
                                  ----------

        Shares          Vesting Schedule
        ---------       ----------------
CSH     679,679         339,840 shares are Vested Shares immediately;
        (license)       5,664 shares become Vested Shares on the first day of
                        each calendar month commencing after the date hereof;
                        provided, however, that if Dr. Thomas Marr ("Marr")
                        leaves the employ of CSH and becomes an employee of the
                        Corporation, all shares become Vested Shares; provided
                        further, that notwithstanding the above provisions, if
                        CSH terminates Marr's employment not for cause and Marr
                        does not become an employee of the Corporation, all
                        shares which have not yet become Vested Shares will
                        always remain Unvested Shares.

                                       10

Source: [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}, [{"source": "alea-institute/alea-institute/kl3m-data-edgar-agreements/train-00003-of-00352.parquet"}]]